Expanded Access for IMMU-132

Sponsor: Gilead Sciences

Expanded Access

Approved for Marketing

Sponsor score: 60

Inactive

ClinicalTrials ID:NCT04320693

This expanded access program provides IMMU-132 to eligible participants. IMMU-132 is administered via intravenous infusion on Days 1 and 8 of each 21-day cycle. Eligibility criteria are not specified in the provided information. The program aims to offer access to this investigational drug for those who meet the necessary requirements.

Patient Parameters

Parameter	Options

Program Overview

This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Get This Program In Your Inbox

You can sign up and apply your patients for this program.